Singapore markets closed

Straits Times Index
3,313.48
+8.49(+0.26%)
Nikkei
38,787.38
-132.88(-0.34%)
Hang Seng
19,553.61
+177.08(+0.91%)
FTSE 100
8,420.26
-18.39(-0.22%)
Bitcoin USD
66,932.52
+1,349.55(+2.06%)
CMC Crypto 200
1,369.64
-4.20(-0.31%)

JNJ Sep 2024 160.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

2.9900

+0.0300

(+1.01%)

As of 03:32PM EDT. Market open.

Loading interactive chart…

Simply Wall St.
Johnson & Johnson Insiders Sell US$6.8m Of Stock, Possibly Signalling Caution
The fact that multiple Johnson & Johnson ( NYSE:JNJ ) insiders offloaded a considerable amount of shares over the past...
Reuters
J&J-backed startup Rapport files for US IPO
Rapport, which develops small molecule medicines for patients suffering from central nervous system disorders, is gearing up for a listing as the IPO market recovers from a slump amid increasing hopes of a soft landing for the economy. The company said it will be selling shares in the IPO, but did not disclose how many nor the price range. Rapport's net loss widened to $34.8 million in 2023 from $10.7 million a year earlier.
Zacks
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.